• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Clinical Study Shows USANA Celavive's Resurfacing Serum to Improve Appearance of Skin in Just Two Weeks

    4/14/25 7:27:00 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $USNA alert in real time by email

    SALT LAKE CITY, April 14, 2025 /PRNewswire/ -- USANA Health Sciences, Inc., a global leader in cellular nutrition, recently conducted a clinical study on its Celavive Resurfacing Serum to evaluate the efficacy and tolerance of the product. The results showed that Resurfacing Serum was well-tolerated by all subjects and users showed statistically significant improvements in the appearance of their skin in just two weeks.

    Clinical Study Shows USANA Celavive's Resurfacing Serum to Improve Appearance of Skin in Just Two Weeks

    To learn more about USANA and the science behind its products, please visit USANA.com.  

    "We are very pleased with the results of the Resurfacing Serum clinical study, and hope this will resonate well with our customer base," said Dr. Kathryn Armstrong, USANA's chief scientific officer. "Clinical studies are the best way to show the efficacy of a product, and the outcome of this study demonstrates the high quality of our Resurfacing Serum and USANA as a whole. As a company dedicated to science and quality, USANA invests a significant amount in research and development so it is imperative we provide our customers with the most effective products possible."

    The clinical study included 33 women with mild to moderate skin concerns, ranging between 39 and 65 years old with and average age of 56, and spanned different races and ethnicities.

    Clinical skin measurements were taken before the participants began using Resurfacing Serum, and again after using the product for two, four, eight, and 12 weeks. The participants also completed a self-assessment questionnaire to evaluate how they felt about their skin after using the product.

    Key findings of the study include:

    • Visible results in as little as four weeks
    • Over the 12-week course of the study, measurements showed a:
      • 15.8% reduction in the appearance of fine lines
      • 11.6% reduction in the appearance of pores
      • 23% reduction in acute visible hyperpigmentation
      • 8.9% improvement in the apparent clarity of the skin
      • 8.6% improvement in the radiant appearance of the skin
    • 81.8% of participants reported it was the best their skin had felt in a long time
    • 97% of participants would recommend the product

    USANA's Resurfacing Serum is formulated to visibly transform the look of your skin with a powerful blend of alpha/beta hydroxy acids, niacinamide, peptides, and bakuchiol—a naturally-derived retinol alternative.

    The unique combination of ingredients is unlike anything on the market in the way of efficacy and results. Upon application, it will help skin feel smoother and glowing. Long-term use will help reduce the appearance of dark spots and visible redness, while also improving fine lines and wrinkles.

    About USANA

    USANA (NYSE:USNA) prides itself on providing consumers with quality nutritional and lifestyle products. From its award-winning supplements to its innovative Celavive skincare and Active Nutrition lines, USANA has proven for over 30 years why it's a company you can trust. How about giving us a try? Shop at USANA.com or learn more at whatsupUSANA.com.

    Media Contact:

    (801) 954-7645

    media(at)USANAinc(dot)com

    USANA logo. (PRNewsfoto/USANA)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/clinical-study-shows-usana-celavives-resurfacing-serum-to-improve-appearance-of-skin-in-just-two-weeks-302427190.html

    SOURCE USANA

    Get the next $USNA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $USNA

    DatePrice TargetRatingAnalyst
    6/23/2023Buy
    Sidoti
    7/7/2022$78.00 → $53.00Hold → Underperform
    Jefferies
    4/14/2022$86.00Neutral
    DA Davidson
    More analyst ratings

    $USNA
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by USANA Health Sciences Inc.

    SCHEDULE 13G/A - USANA HEALTH SCIENCES INC (0000896264) (Subject)

    3/27/26 1:51:55 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 10-K filed by USANA Health Sciences Inc.

    10-K - USANA HEALTH SCIENCES INC (0000896264) (Filer)

    3/16/26 2:57:18 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 144 filed by USANA Health Sciences Inc.

    144 - USANA HEALTH SCIENCES INC (0000896264) (Subject)

    3/3/26 4:38:42 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    $USNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Fuller Gilbert A

    4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)

    3/20/26 4:53:49 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    CHIEF INFORMATION OFFICER Benedict Peter sold $88,259 worth of shares (4,553 units at $19.38), closing all direct ownership in the company (SEC Form 4)

    4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)

    3/3/26 6:08:39 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    CHIEF OPERATING OFFICER Noot Walter covered exercise/tax liability with 3,144 shares and converted options into 7,422 shares, increasing direct ownership by 86% to 9,256 units (SEC Form 4)

    4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)

    3/3/26 12:18:37 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    $USNA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    USANA CEO Kevin Guest Calls for Daily Health Routines on World Health Day

    SALT LAKE CITY, April 1, 2026 /CNW/ -- For World Health Day April 7, Kevin Guest, Chairman and CEO of USANA Health Sciences (NYSE:USNA), is calling for a shift away from awareness only and toward execution to improve health. "Most people know how to improve their health; they just don't do it consistently," said Guest. "That gap between knowing and doing is where results suffer."I've found that people aren't lacking information. In fact, they're overwhelmed by it. What's missing is execution because health is shaped by what you do every day, not what you just plan to do."Studies

    4/1/26 7:04:00 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    Tested, Trusted, Approved: USANA CellSentials Earns ConsumerLab.com Seal of Approval for Purity and Potency

    SALT LAKE CITY, March 24, 2026 /PRNewswire/ -- USANA (NYSE:USNA), a global leader in cellular nutrition, today announced that its flagship CellSentials supplement has earned the prestigious ConsumerLab.com Seal of Approval. This highly respected third-party certification is awarded only to products that meet rigorous standards for purity, potency, and label accuracy. Recent health surveys indicate that many Americans fall short in key nutrients—including vitamins A, C, D, and E, as well as zinc and magnesium—making daily supplementation an important tool for supporting overall w

    3/24/26 7:02:00 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    Next-Generation Platforms Scale Across Energy, Wellness, and Smokeless Consumer Segments

    Issued on behalf of Doseology Sciences Inc.Equity-Insider.com VANCOUVER, BC, March 5, 2026 /CNW/ -- Consumers are voting with their wallets, and zero-sugar is winning. Zero-sugar beverages are driving 6x more dollar growth than regular varieties as buyers actively choose clean-label products with natural sweeteners and functional ingredients[1]. The global market is forecast to expand from $350 billion in 2024 toward $500 billion by 2029, fueled by health-conscious consumers who want naturally functional products without heavy processing[1]. This structural shift is creating validated demand for precision-dosed, portable formats across energy and wellness categories, positioning Doseology Sc

    3/5/26 9:00:00 AM ET
    $HLF
    $NHTC
    $NMTC
    Other Pharmaceuticals
    Health Care
    Consumer Specialties
    Consumer Discretionary

    $USNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Sidoti initiated coverage on USANA

    Sidoti initiated coverage of USANA with a rating of Buy

    6/23/23 9:12:38 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    USANA downgraded by Jefferies with a new price target

    Jefferies downgraded USANA from Hold to Underperform and set a new price target of $53.00 from $78.00 previously

    7/7/22 9:35:48 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    DA Davidson initiated coverage on USANA with a new price target

    DA Davidson initiated coverage of USANA with a rating of Neutral and set a new price target of $86.00

    4/14/22 7:45:27 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    $USNA
    Leadership Updates

    Live Leadership Updates

    View All

    Kevin Guest Returns to USANA Health Sciences as CEO

    USANA Health Sciences, Inc. (NYSE:USNA) announced today a leadership transition as part of the Company's ongoing commitment to accelerating growth and enhancing shareholder value. Kevin Guest is returning to lead the Company as Chief Executive Officer, effective immediately. Mr. Guest, who has spent more than three decades at the Company, including eight years as CEO and the last three years as Executive Chairman, has agreed to again serve as USANA's CEO and will continue serving as Chairman. Mr. Guest succeeds Jim Brown, who has stepped down from his position of CEO and President. "We thank Jim for his contributions and his leadership over the past 19 years and in his role as CEO over th

    1/8/26 9:00:00 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    Solstice Advance Materials and Qnity Electronics Set to Join S&P 500; Others to Join S&P SmallCap 600

    NEW YORK, Oct. 27, 2025 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P SmallCap 600: Solstice Advance Materials Inc. (NASD: SOLS) will replace CarMax Inc. (NYSE:KMX) in the S&P 500, and CarMax will replace USANA Health Sciences Inc. (NYSE:USNA) in the S&P SmallCap 600 effective prior to the opening of trading on Friday, October 31. S&P 500 and 100 constituent Honeywell International Inc. (NASD: HON) is spinning off Solstice Advance Materials in a transaction expected to be completed on October 30. Post spin-off, Honeywell International will remain in the S&P 500 and 100. CarMax and USANA Health Sciences no longer represent the large cap and small c

    10/27/25 6:10:00 PM ET
    $CAL
    $DD
    $EMN
    Shoe Manufacturing
    Consumer Discretionary
    Major Chemicals
    Industrials

    USANA Exec. Chairman Kevin Guest Celebrates Guitar Month, Stress Awareness Month for Harmony

    SALT LAKE CITY, April 1, 2025 /PRNewswire/ -- USANA Health Sciences (NYSE:USNA) Executive Chairman Kevin Guest marks April's convergence of International Guitar Month and Stress Awareness Month, as a perfect pairing that celebrates the healing power of music for mental well-being. While music has long been heralded as a universal remedy, the guitar offers far more than just melodies. Studies, stories and specialists alike agree: playing the guitar is a proven method to reduce stress. A passionate, performing guitarist himself, Guest invites others to join the cause. "Music has

    4/1/25 7:47:00 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    $USNA
    Financials

    Live finance-specific insights

    View All

    Next-Generation Platforms Scale Across Energy, Wellness, and Smokeless Consumer Segments

    Issued on behalf of Doseology Sciences Inc.Equity-Insider.com VANCOUVER, BC, March 5, 2026 /CNW/ -- Consumers are voting with their wallets, and zero-sugar is winning. Zero-sugar beverages are driving 6x more dollar growth than regular varieties as buyers actively choose clean-label products with natural sweeteners and functional ingredients[1]. The global market is forecast to expand from $350 billion in 2024 toward $500 billion by 2029, fueled by health-conscious consumers who want naturally functional products without heavy processing[1]. This structural shift is creating validated demand for precision-dosed, portable formats across energy and wellness categories, positioning Doseology Sc

    3/5/26 9:00:00 AM ET
    $HLF
    $NHTC
    $NMTC
    Other Pharmaceuticals
    Health Care
    Consumer Specialties
    Consumer Discretionary

    USANA Health Sciences Reports Fourth Quarter and Full Year 2025 Results and Provides Fiscal Year 2026 Outlook

    USANA Health Sciences, Inc. (NYSE:USNA) today announced financial results for its fiscal fourth quarter and fiscal year ended January 3, 2026. Key Financial and Operating Results   Q4 2025   Q4 2024   FY 2025   FY 2024 Net sales $226.2   $213.6   $925.3   $854.5 Net (loss) earnings* $-1.8   $4.5   $10.8   $42.0 Diluted EPS $-0.10   $0.23   $0.58   $2.19 Adjusted diluted EPS(1) $0.60   $0.64   $1.93   $2.59 Adjusted EBITDA(2) $27.3

    2/17/26 4:15:00 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    USANA Health Sciences Provides Preliminary Fiscal Year 2025 Net Sales and Issues Initial Fiscal Year 2026 Net Sales Outlook

    USANA Health Sciences, Inc. (NYSE:USNA) today announced preliminary fiscal year 2025 net sales and initial net sales guidance for fiscal year 2026 ahead of its presentation at the 28th Annual ICR Conference. At the conference, Doug Hekking, CFO, and Walter Noot, COO, will discuss USANA's strategy, including the Company's initial fiscal year 2026 sales outlook. Preliminary Fiscal Year 2025 Net Sales Results The Company currently anticipates fiscal year 2025 consolidated net sales of approximately $925 million, ahead of its most recently issued guidance of approximately $920 million. Initial Fiscal Year 2026 Net Sales Outlook The Company is issuing its initial net sales outlook for fi

    1/12/26 6:15:00 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    $USNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by USANA Health Sciences Inc. (Amendment)

    SC 13G/A - USANA HEALTH SCIENCES INC (0000896264) (Subject)

    2/13/24 10:49:58 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by USANA Health Sciences Inc. (Amendment)

    SC 13G/A - USANA HEALTH SCIENCES INC (0000896264) (Subject)

    2/13/23 11:26:45 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by USANA Health Sciences Inc. (Amendment)

    SC 13G/A - USANA HEALTH SCIENCES INC (0000896264) (Subject)

    2/11/22 3:48:24 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care